Moniyot-131 (Sodium Iodide (131i))

Sodium Iodide-131, the active ingredient in Moniyot-131, is a radiopharmaceutical presented as an oral solution for oral use. It treats thyroid disease such as hyperthyroidism, thyroid cancer, and benign thyroid nodules by delivering targeted radiation to thyroid tissue.

GNH USA supplies Moniyot-131 as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Moniyot-131 is used in the management of thyroid disorders that take up iodine via the sodium‑iodide symporter. - Hyperthyroidism: reduces excess thyroid hormone production by ablating overactive thyroid tissue. - Thyroid cancer (adjuvant ablation): destroys residual thyroid cells after surgery to lower recurrence risk. - Benign thyroid nodules: shrinks nodular tissue that demonstrates iodine uptake. - Diagnostic imaging of thyroid tissue: provides functional imaging to assess thyroid tissue distribution.

Adverse reactions to Moniyot-131 may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Salivary gland irritation: transient swelling or discomfort. - Dry mouth: reduced salivary flow. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Bone marrow suppression: decreased blood cell production. - Severe hypothyroidism: excessive loss of thyroid function requiring hormone replacement. - Radiation‑induced secondary malignancies: rare risk of new cancers.

When using Moniyot-131, several safety considerations should be observed. - Pregnancy: avoid use unless benefits outweigh risks, as fetal thyroid may be affected. - Breastfeeding: discontinue breastfeeding during treatment and for a period afterward. - Renal impairment: adjust monitoring because iodine clearance may be reduced. - Concomitant thyroid hormone therapy: assess need for dose adjustments after ablation. - Radiation safety: ensure proper handling and limit exposure to staff and family members. - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Moniyot-131 can interact with other agents that affect thyroid function or radiation exposure.

Major Interactions (Avoid): - Antithyroid drugs (e.g., methimazole, propylthiouracil): may reduce uptake of radioiodine, diminishing therapeutic effect. - High‑iodine diet or iodine‑containing contrast agents: compete for NIS, lowering efficacy.

Moderate Interactions (Monitor Closely): - Levothyroxine: dose may need adjustment after ablation. - Chemotherapeutic agents causing bone marrow suppression: increased risk of hematologic toxicity. - Salivary stimulants (e.g., pilocarpine): may exacerbate salivary gland irritation.